Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1299-1304

  Brophy, Donald F ^a,b   Martin, E J ^a,b   Best, A M ^a   Gehr, T W B ^b   Carr, M E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifactor Xa activity; Clot elastic modulus; Enoxaparin; Platelet contractile force; Thrombin generation time

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EX VIVO STUDY; FEMALE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; THROMBIN TIME; THROMBOCYTE ACTIVATION; YOUNG MODULUS;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; THROMBIN; THROMBIN TIME; TIME FACTORS;

EID: 13244253716     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00789.x     Document Type: Article

References (29)

1. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41.
2. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications. A review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-5.
3. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E, Leger P, Fontan B, Massip P, Montastruc JL. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Safety 2003; 26: 197-207.
4. Chow SL, Zammit K, West K, Dannenhoffer MA, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-90.
5. Cadroy Y, Pourrat J, Baladre M, Saivin S, Houin G, Montrastruc J, Vernier I, Boneu B. Delayed elimination of enoxapaxine in patients with chronic renal insufficiency. Thrombosis Res 1991; 63: 385-90.
6. Collett JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-2.
7. Sanderink J, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Res 2002; 105: 225-31.
8. Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995; 25: 203-11.
9. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Laboratory Med 1998; 122: 799-807.
10. Carr ME, Martin EJ, Kuhn JG, Spiess MD. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemost 2003; 1: 1977-83.
11. Carr ME. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophy 2003; 38: 55-78.
12. Butenas S, van't Veer C, Mann KG. 'Normal' thrombin generation. Blood 1999; 94: 2169-78.
13. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003; 23: 17-25.
14. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001; 8: 263-9.
15. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
16. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9
17. Krishnaswami A, Carr ME, Jesse RL, Kontos MC, Minisi AJ, Ornato JP, Vetrovec GW, Martin EJ. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb Haemost 2002; 88: 739-44.
18. Al-Obaidi MK, Philippou H, Stubbs PJ, Adami A, Amersey R, Noble MM, Lane DA. Relationship between homocysteine factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101: 372-7.
19. Carr ME, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003; 89 803-11.
20. Carr ME, Krishnaswami A, Martin EJ. Platelet contractile force (PCF) and clot modulus (CEM) are elevated in diabetic patients with chest pain. Diabet Med 2002; 19: 862-6.
21. Carr ME, Angchaisuksiri P, Carr SL, Martin EJ. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. Cell Biochem Biophys 2003; 39: 89-99.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers Nm Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130 461-70.
23. Carr ME Jr, Martin EJ, Carr SL. Delayed reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul Fibrinolysis 2002; 13: 193-7.
24. Carr ME Jr, Carr SL, Tildon T, Fisher LM, Martin EJ, Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. J Thromb Haemost 2003; 1: 243-9
25. Carr ME Jr, Carr SL, Greilich PE. Heparin ablates force development during platelet mediated clot retraction. Thromb Haemost 1996; 75: 674-8.
26. Carr ME, Park A, Zekert SL, Marques D, Goldman ID, Sobel M. Anticoagulant and antiplatelet activities of heparin and low molecular weight derivatives. Proceedings of the 1993 Annual Meeting of the American Society of Hematology. Blood 1993; 82: 603a (Abstract 2396).
27. Carr ME Jr, Zekert SL. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol 1994; 266 (3 Part 2): H1195-201.
28. Hartert H, Schraeder JA. The physical and biological constants of thromboelastography. Biorheology 1962; 1: 31.
29. Hartert H. Fibrin elasticity and coagulation. Biorrheology 1988; 25: 137-45.